Identification of cell cycle dependent methotrexate resistance in placenta site trophoblastic tumors

Jing Xu, Ling Zhang, Qiyu Liu, Luyao Ren, Ke Li, Baozhu Cai, Yunke Huang, Jing Wang, Qin Li, Yu Kang, Congjian XuResearch 2020 · DOI

Introduction

Placental Site Trophoblastic Tumor (PSTT) is a rare and aggressive form of gestational trophoblastic neoplasia. Unlike choriocarcinoma, which is often highly sensitive to chemotherapy, PSTT is notoriously chemoresistant. Currently, the clinical gold standard for treatment is a hysterectomy, which is a devastating option for patients wishing to preserve fertility. The biological mechanisms driving this resistance, particularly to frontline treatments like methotrexate (MTX), have remained poorly understood. This study aimed to elucidate why PSTT is resistant to MTX and identify the molecular pathways responsible for this phenotype.

Methods

Researchers employed a multi-disciplinary approach to bridge the gap between clinical observation and molecular biology:

  • Cell Line Establishment: Three novel PSTT cell lines (PSTT-1, 2, and 3) were successfully created from surgically resected patient tissues.
  • In Vitro & In Vivo Testing: Drug sensitivity (IC50) was measured across several chemotherapeutics. Findings were validated in vivo using a Mini-Patient-Derived Xenograft (Mini-PDX) model, where tumor cells are encapsulated and implanted in mice to simulate the human tumor environment.
  • Cell Cycle Analysis: Flow cytometry was used to compare the cell cycle distribution of PSTT cells against sensitive choriocarcinoma cells (JEG-3 and JAR).
  • Multi-Omics Profiling: RNA sequencing (RNA-seq) was performed to analyze gene expression, and Whole Genome Sequencing (WES) was used to identify potential functional mutations.

Key Results

Massive Resistance Gap

The study found a staggering difference in drug sensitivity. The IC50 for MTX in PSTT lines was approximately 4.5–5.1 mg/ml, whereas in choriocarcinoma lines, it was a mere 0.01 µg/ml—representing a nearly 50,000-fold increase in resistance. The Mini-PDX model confirmed these findings in vivo; while drugs like Actinomycin-D showed some inhibitory effect, MTX had no significant impact on PSTT tumor growth.

The "S-Phase" Shield and G1 Arrest

MTX is a folate antagonist that specifically targets cells during DNA synthesis (S-phase). Cell cycle analysis revealed that PSTT cells have a significantly lower proportion of cells in the S-phase compared to choriocarcinoma. Instead, PSTT cells appear to arrest in the G1 phase. By failing to progress through the G1/S transition, the tumor cells effectively "hide" from the window of vulnerability where MTX is effective.

Genomic and Transcriptomic Signatures

RNA-seq revealed 6,885 differentially expressed genes. Specifically, gene clusters related to cell cycle biological processes were significantly downregulated in PSTT, explaining the sluggish cell cycle. Furthermore, the study identified six candidate genes (MTBP, FBXO5, NEK2, POLE, MSH2, and BLM) that were both mutated and involved in the G1/S transition, likely driving the slow-growth phenotype.

Discussion and Future Directions

The findings suggest that PSTT resistance to MTX is a direct result of cell cycle stalling. The dysregulation of the G1/S transition allows these cells to evade cycle-dependent chemotherapeutics. While the study is limited by the rarity of the disease and the small number of established cell lines, it provides a critical molecular roadmap.

Future research will focus on functional "knock-in" or "knock-out" experiments for the identified candidate genes. Understanding how to manipulate these pathways to "sensitize" PSTT cells to chemotherapy could eventually lead to effective fertility-sparing treatments for patients with this aggressive disease.

Summary updated

Abstract

Abstract Background The purpose is to study the mechanism of chemotherapy resistance in Placental site trophoblastic tumor(PSTT).Methods We established PSTT cell lines by primary culture of a surgically resected PSTT tissues and identified the expression of immune-phenotype markers(HLA-G, β-catenin, CD146, Muc4, hPL, hCG) by immunofluorescence. We measured the IC50 value of methotrexate(MTX), etoposide(VP-16), actinomycin-D(Act-D), cisplatin(DDP), fluorouracil(5-FU) and paclitaxel(TAX) in PSTTs and used a special Mini patient-derived xenograft (Mini PDX) model to evaluate effectiveness of these drugs in vivo . Given that MTX is a cell cycle-dependent chemotherapeutic, we analyzed cell cycle characteristics of PSTT and choriocarcinoma cell lines by flow cytometry and then analyzed RNA profiles and WGS data of the PSTT cell lines to identify the potential mechanism.Results We identified the expression of HLA-G, β-catenin, CD146, hPL and hCG in PSTT cell lines. The IC50 value of MTX was 4.922 mg/ml in PSTT-1, 4.525 mg/ml in PSTT-2, 5.117 mg/ml in PSTT-3, 0.0166 µg/ml in JEG-3 cells (p༜0.001), and 0.01 µg/ml in JAR cells (p༜0.001), with nearly 50,000-fold increase in PSTTs than in choriocarcinoma, indicating that PSTTs are resistant to MTX in vitro. The Mini PDX model revealed that PSTTs are also resistant to MTX in vivo . Cell cycle analysis showed dysregulation of G1/S transition and cell cycle arrest in PSTT cell lines. RNA sequencing profile also identified cell cycle-associated genes which were differentially expressed in PSTT cells than in choriocarcinoma cell.Conclusions We found PSTTs are resistant to MTX in vitro and in vivo compared to choriocarcinoma. Mechanisms could be focused on dysregulation of the G1/S transition and cell cycle arrest.
BibTeX
@inproceedings{xu2020identification,
  author = {Jing Xu and Ling Zhang and Qiyu Liu and Luyao Ren and Ke Li and Baozhu Cai and Yunke Huang and Jing Wang and Qin Li and Yu Kang and Congjian Xu},
  title = {{Identification of cell cycle dependent methotrexate resistance in placenta site trophoblastic tumors}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-24085/v1},
}
Figure